\-\ Texto\\:\\ \ \(0\)\
\-\ radiologic\\ findings\\:\\ axial\\ ct\\ of\\ abd\\ w\\/contrast\\ \ \(0\)\
\-\ \\ \\ 4\\ cm\\ rounded\\ solid\\ mass\\ in\\ upper\\ left\\ kidney\\ with\\ extracapsular\\ spread\\.\\ likely\\ renal\\ cell\\ carcinoma\\.\\ no\ \(0\)\
\-\ \\ \\ evidence\\ of\\ regional\\ lymphadenopathy\\ or\\ renal\\ vein\\ involvement\\.\\ evidence\\ of\\ left\\ perirenal\\ hematoma\\ \\-\ \(0\)\
\-\ \\ \\ resolving\\.\\ liver\\ and\\ lungs\\ normal\\.\\ \ \(0\)\
\-\ \\ \\ multiple\\ bilateral\\ renal\\ cysts\\,\\ 6\\.5\\ by\\ 5cm\\ on\\ right\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\ \(60\)\
\-\ primary\\ tumors\\:\\ \ \(2\)\
\-\ \\ \\ \\-oncocytoma\\ \\-\\ indistinguishable\\ from\\ renal\\ cell\\ ca\\ preoperatively\\.\\ \ \(1\)\
\-\ \\ \\ \\-angiomyolipoma\\ \\-\\ usually\\ have\\ fat\\ density\\ on\\ ct\\ \ \(0\)\
\-\ \\ \\ \\-transitional\\ cell\\ ca\\ \\-usually\\ in\\ renal\\ pelvis\\ and\\ collecting\\ system\\ \ \(0\)\
\-\ \\ \\ \\-adrenal\\ tumors\\ \ \(0\)\
\-\ \\ \\ \\-simple\\ cyst\\ \\-smooth\\,\\ thin\\ wall\\ on\\ ct\\,\\ sharply\\ demarcated\\,\\ no\\ contrast\\ uptake\\ \ \(0\)\
\-\ \\ \\ secondary\\ tumors\\:\\ \ \(1\)\
\-\ \\ \\ \\-metastatic\\ disease\\ \\-\\ lung\\,\\ breast\\,\\ stomach\\ ca\\ \ \(1\)\
\-\ \\ \\ \\-lymphoma\ \(1\)\
\-\ request\\ ct\\ abdomen\\ with\\ contrast\\.\\ \ \(0\)\
\-\ \\ \\ 60\\ yo\\ male\\ had\\ a\\ large\\ left\\ perinephric\\ hematoma\\ after\\ mild\\ blunt\\ trauma\\.\\ unable\\ to\\ evaluate\\ left\\ kidney\\ on\\ prior\\ study\\.\\ please\\ evaluate\\.\ \(0\)\
\-\ renal\\ cell\\ ca\\ is\\ relatively\\ rare\\,\\ comprising\\ 2\\.3\\%\\ of\\ all\\ adult\\ cancers\\.\\ it\\ affects\\ males\\ twice\\ as\\ often\\ as\\ females\\ and\\ incidence\\ peaks\\ in\\ the\\ sixth\\ decade\\ of\\ life\\.\\ renal\\ tumors\\ are\\ being\\ detected\\ more\\ commonly\\ as\\ incidental\\ findings\\ with\\ the\\ increased\\ use\\ of\\ ct\\.\\ symptomatic\\ patients\\ may\\ present\\ with\\ flank\\ pain\\,\\ hematuria\\,\\ and\\/or\\ abdominal\\ mass\\.\\ this\\ tumor\\ invades\\ perinephric\\ tissue\\ but\\ has\\ not\\ metastasized\\ to\\ regional\\ nodes\\ or\\ to\\ distant\\ sites\\.\\ the\\ stage\\ is\\ thus\\ t3an0m0\\.\\ \ \(0\)\
\-\ \\ \\ the\\ treatment\\ for\\ renal\\ cell\\ ca\\ is\\ radical\\ nephrectomy\\.\\ patients\\ with\\ tumors\\ extending\\ beyond\\ the\\ renal\\ capsule\\ have\\ a\\ 50\\%\\ disease\\-free\\ survival\\ 5\\ yrs\\ postoperatively\\.\\ the\\ cysts\\ seen\\ bilaterally\\ are\\ benign\\ and\\ have\\ no\\ association\\ with\\ the\\ malignancy\\.\\ \ \(0\)\
\-\ \\ this\\ case\\ emphasizes\\ the\\ importance\\ of\\ follow\\-up\\ studies\\,\\ since\\ the\\ patient\\'s\\ initial\\ ct\\ showed\\ a\\ perirenal\\ hematoma\\ obscuring\\ the\\ left\\ kidney\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.08335959576162562\ \(0\)\
\-\ ca\\:\\ 0\\.06459799540608799\ \(0\)\
\-\ tumors\\:\\ 0\\.05210578502711852\ \(0\)\
\-\ cell\\:\\ 0\\.044965728147691286\ \(0\)\
\-\ perirenal\\:\\ 0\\.04167287760498784\ \(0\)\
\-\ regional\\:\\ 0\\.03515792884613209\ \(0\)\
\-\ perinephric\\:\\ 0\\.03515792884613209\ \(0\)\
\-\ hematoma\\:\\ 0\\.02961980725735802\ \(0\)\
\-\ kidney\\:\\ 0\\.029321916769967628\ \(0\)\
\-\ \\-oncocytoma\\:\\ 0\\.028621813064826297\ \(0\)\
\-\ t3an0m0\\:\\ 0\\.028621813064826297\ \(0\)\
\-\ \\-angiomyolipoma\\:\\ 0\\.026371335205865435\ \(0\)\
\-\ \\-usually\\:\\ 0\\.026371335205865435\ \(0\)\
\-\ \\-adrenal\\:\\ 0\\.026371335205865435\ \(0\)\
\-\ disease\\-free\\:\\ 0\\.026371335205865435\ \(0\)\
\-\ \\-transitional\\:\\ 0\\.025054890049670094\ \(0\)\
\-\ \\-simple\\:\\ 0\\.025054890049670094\ \(0\)\
\-\ \\-smooth\\:\\ 0\\.025054890049670094\ \(0\)\
\-\ metastasized\\:\\ 0\\.02412085734690457\ \(0\)\
\-\ emphasizes\\:\\ 0\\.02412085734690457\ \(0\)\
\-\ \\-\\:\\ 0\\.0237886812819268\ \(0\)\
\-\ preoperatively\\:\\ 0\\.02339636529718311\ \(0\)\
\-\ ct\\:\\ 0\\.023285136105039798\ \(0\)\
\-\ evaluate\\:\\ 0\\.02243004063803294\ \(0\)\
\-\ invades\\:\\ 0\\.02230392297049086\ \(0\)\
\-\ cysts\\:\\ 0\\.02173674209630758\ \(0\)\
\-\ w\\/contrast\\:\\ 0\\.021487967034513892\ \(0\)\
\-\ peaks\\:\\ 0\\.021487967034513892\ \(0\)\
\-\ comprising\\:\\ 0\\.02114588743822225\ \(0\)\
\-\ extracapsular\\:\\ 0\\.02083643880249392\ \(0\)\
\-\ postoperatively\\:\\ 0\\.02083643880249392\ \(0\)\
\-\ indistinguishable\\:\\ 0\\.020294055410730396\ \(0\)\
\-\ \\-lymphoma\\:\\ 0\\.020294055410730396\ \(0\)\
\-\ 5cm\\:\\ 0\\.02005344511153\ \(0\)\
\-\ 2\\.3\\:\\ 0\\.02005344511153\ \(0\)\
\-\ obscuring\\:\\ 0\\.02005344511153\ \(0\)\
\-\ \\-metastatic\\:\\ 0\\.01982944228202691\ \(0\)\
\-\ 6\\.5\\:\\ 0\\.019619901628982847\ \(0\)\
\-\ request\\:\\ 0\\.01942306844126715\ \(0\)\
\-\ demarcated\\:\\ 0\\.019237489175553034\ \(0\)\
\-\ sixth\\:\\ 0\\.01830345647278751\ \(0\)\
\-\ have\\:\\ 0\\.0180237475165431\ \(0\)\
\-\ sharply\\:\\ 0\\.017921044019357693\ \(0\)\
\-\ twice\\:\\ 0\\.017689034396039038\ \(0\)\
\-\ yrs\\:\\ 0\\.017578964423066046\ \(0\)\
\-\ resolving\\:\\ 0\\.017369423770021986\ \(0\)\
\-\ radical\\:\\ 0\\.017369423770021986\ \(0\)\
\-\ cancers\\:\\ 0\\.016727132395574197\ \(0\)\
\-\ blunt\\:\\ 0\\.016564760900201918\ \(0\)\
\-\ decade\\:\\ 0\\.016335483084572198\ \(0\)\
\-\ distant\\:\\ 0\\.01619115918012144\ \(0\)\
\-\ importance\\:\\ 0\\.01619115918012144\ \(0\)\
\-\ beyond\\:\\ 0\\.016121333838494935\ \(0\)\
\-\ males\\:\\ 0\\.015986032876155427\ \(0\)\
\-\ affects\\:\\ 0\\.01579309969280867\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.015731254903942782\ \(0\)\
\-\ carcinoma\\:\\ 0\\.015726803052051083\ \(0\)\
\-\ left\\:\\ 0\\.015521189436248615\ \(0\)\
\-\ females\\:\\ 0\\.01543855653707818\ \(0\)\
\-\ sites\\:\\ 0\\.015118945911061124\ \(0\)\
\-\ capsule\\:\\ 0\\.015019037928376859\ \(0\)\
\-\ survival\\:\\ 0\\.0148747140239261\ \(0\)\
\-\ abd\\:\\ 0\\.014691749944214636\ \(0\)\
\-\ detected\\:\\ 0\\.014647575749228339\ \(0\)\
\-\ evidence\\:\\ 0\\.014548328463421285\ \(0\)\
\-\ radiologic\\:\\ 0\\.01443529406330999\ \(0\)\
\-\ patients\\:\\ 0\\.014360874021857312\ \(0\)\
\-\ collecting\\:\\ 0\\.01415964651854867\ \(0\)\
\-\ adult\\:\\ 0\\.013905580944198838\ \(0\)\
\-\ thus\\:\\ 0\\.013802500754865787\ \(0\)\
\-\ rounded\\:\\ 0\\.013669961811618205\ \(0\)\
\-\ association\\:\\ 0\\.01348077704498192\ \(0\)\
\-\ spread\\:\\ 0\\.01342008830143597\ \(0\)\
\-\ hematuria\\:\\ 0\\.013160209380417995\ \(0\)\
\-\ flank\\:\\ 0\\.01305106454016155\ \(0\)\
\-\ \\%\\:\\ 0\\.012943643073675374\ \(0\)\
\-\ unable\\:\\ 0\\.01281812978412635\ \(0\)\
\-\ incidence\\:\\ 0\\.012719735792258399\ \(0\)\
\-\ as\\:\\ 0\\.012590040641825919\ \(0\)\
\-\ nodes\\:\\ 0\\.012531465475211811\ \(0\)\
\-\ contrast\\:\\ 0\\.012420621342908477\ \(0\)\
\-\ please\\:\\ 0\\.012310512672468254\ \(0\)\
\-\ stomach\\:\\ 0\\.012268070849197628\ \(0\)\
\-\ 60\\:\\ 0\\.012103643145240631\ \(0\)\
\-\ life\\:\\ 0\\.012103643145240631\ \(0\)\
\-\ relatively\\:\\ 0\\.011871633521921979\ \(0\)\
\-\ stage\\:\\ 0\\.011834527366650477\ \(0\)\
\-\ findings\\:\\ 0\\.011810629453181556\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.011797840498942901\ \(0\)\
\-\ and\\/or\\:\\ 0\\.011725687457434101\ \(0\)\
\-\ thin\\:\\ 0\\.011403290636063062\ \(0\)\
\-\ solid\\:\\ 0\\.011066060560085649\ \(0\)\
\-\ uptake\\:\\ 0\\.01102267345679939\ \(0\)\
\-\ symptomatic\\:\\ 0\\.01102267345679939\ \(0\)\
\-\ \\:\\:\\ 0\\.01100917028562336\ \(0\)\
\-\ use\\:\\ 0\\.010965711412478256\ \(0\)\
\-\ system\\:\\ 0\\.010923636267535059\ \(0\)\
\-\ rare\\:\\ 0\\.010773864281406807\ \(0\)\
\-\ malignancy\\:\\ 0\\.010721070382472454\ \(0\)\
\-\ 50\\:\\ 0\\.010555188365726638\ \(0\)\
\-\ lungs\\:\\ 0\\.010505807136299597\ \(0\)\
\-\ incidental\\:\\ 0\\.010505807136299597\ \(0\)\
\-\ commonly\\:\\ 0\\.010469257933297537\ \(0\)\
\-\ studies\\:\\ 0\\.010362015966815455\ \(0\)\
\-\ breast\\:\\ 0\\.010235577739709586\ \(0\)\
\-\ since\\:\\ 0\\.010190794226292911\ \(0\)\
\-\ involvement\\:\\ 0\\.010168632002038366\ \(0\)\
\-\ pelvis\\:\\ 0\\.010081465605816976\ \(0\)\
\-\ vein\\:\\ 0\\.010038744551993887\ \(0\)\
\-\ being\\:\\ 0\\.009668142781819995\ \(0\)\
\-\ benign\\:\\ 0\\.009574838854003901\ \(0\)\
\-\ liver\\:\\ 0\\.009565654255950401\ \(0\)\
\-\ on\\:\\ 0\\.009401181978771794\ \(0\)\
\-\ extending\\:\\ 0\\.00932700989883051\ \(0\)\
\-\ initial\\:\\ 0\\.009193448517140611\ \(0\)\
\-\ density\\:\\ 0\\.00912867323655831\ \(0\)\
\-\ study\\:\\ 0\\.00912867323655831\ \(0\)\
\-\ bilaterally\\:\\ 0\\.00911267934585683\ \(0\)\
\-\ showed\\:\\ 0\\.00909676385689512\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.009026094128057605\ \(0\)\
\-\ often\\:\\ 0\\.008852186845843027\ \(0\)\
\-\ \\,\\:\\ 0\\.008789287841470369\ \(0\)\
\-\ fat\\:\\ 0\\.008438027022342967\ \(0\)\
\-\ usually\\:\\ 0\\.008425091733333634\ \(0\)\
\-\ no\\:\\ 0\\.008380949519842227\ \(0\)\
\-\ yo\\:\\ 0\\.00834854390682715\ \(0\)\
\-\ primary\\:\\ 0\\.008218780074336678\ \(0\)\
\-\ abdomen\\:\\ 0\\.008218780074336678\ \(0\)\
\-\ 5\\:\\ 0\\.008117403968974557\ \(0\)\
\-\ wall\\:\\ 0\\.00803623090986606\ \(0\)\
\-\ lung\\:\\ 0\\.00803623090986606\ \(0\)\
\-\ axial\\:\\ 0\\.007918154143077505\ \(0\)\
\-\ all\\:\\ 0\\.00784715418646523\ \(0\)\
\-\ likely\\:\\ 0\\.007825616772518366\ \(0\)\
\-\ secondary\\:\\ 0\\.007756590800353271\ \(0\)\
\-\ 4\\:\\ 0\\.007730428263568329\ \(0\)\
\-\ mass\\:\\ 0\\.007717279265893277\ \(0\)\
\-\ trauma\\:\\ 0\\.0075876908498634064\ \(0\)\
\-\ are\\:\\ 0\\.007564116055387025\ \(0\)\
\-\ cyst\\:\\ 0\\.0074557504416431905\ \(0\)\
\-\ cm\\:\\ 0\\.007441415966938266\ \(0\)\
\-\ mild\\:\\ 0\\.007306017707568627\ \(0\)\
\-\ prior\\:\\ 0\\.007123742766890791\ \(0\)\
\-\ more\\:\\ 0\\.006938884121143398\ \(0\)\
\-\ abdominal\\:\\ 0\\.006934802721175699\ \(0\)\
\-\ increased\\:\\ 0\\.006787288252596285\ \(0\)\
\-\ bilateral\\:\\ 0\\.006733174445826117\ \(0\)\
\-\ upper\\:\\ 0\\.006695066575872463\ \(0\)\
\-\ tissue\\:\\ 0\\.006576042819651279\ \(0\)\
\-\ or\\:\\ 0\\.006503394473790309\ \(0\)\
\-\ tumor\\:\\ 0\\.006468286693541595\ \(0\)\
\-\ present\\:\\ 0\\.006266262188089873\ \(0\)\
\-\ this\\:\\ 0\\.006241150735806059\ \(0\)\
\-\ it\\:\\ 0\\.006236520729003301\ \(0\)\
\-\ \\'s\\:\\ 0\\.006117034475217679\ \(0\)\
\-\ may\\:\\ 0\\.006085481717201701\ \(0\)\
\-\ case\\:\\ 0\\.006069819587231399\ \(0\)\
\-\ large\\:\\ 0\\.0060666962072437654\ \(0\)\
\-\ had\\:\\ 0\\.0059865253871451566\ \(0\)\
\-\ but\\:\\ 0\\.005917218509849148\ \(0\)\
\-\ multiple\\:\\ 0\\.005843525985322302\ \(0\)\
\-\ after\\:\\ 0\\.005740263644835073\ \(0\)\
\-\ treatment\\:\\ 0\\.005615639479223659\ \(0\)\
\-\ seen\\:\\ 0\\.005482557191778216\ \(0\)\
\-\ is\\:\\ 0\\.005476858231020055\ \(0\)\
\-\ has\\:\\ 0\\.005210064839267136\ \(0\)\
\-\ male\\:\\ 0\\.0050169010970372505\ \(0\)\
\-\ by\\:\\ 0\\.004619710724821023\ \(0\)\
\-\ disease\\:\\ 0\\.004534862146804234\ \(0\)\
\-\ the\\:\\ 0\\.00448861313972811\ \(0\)\
\-\ normal\\:\\ 0\\.004349391086360718\ \(0\)\
\-\ to\\:\\ 0\\.0041597543030161\ \(0\)\
\-\ from\\:\\ 0\\.004111804263487702\ \(0\)\
\-\ in\\:\\ 0\\.0041045184753920935\ \(0\)\
\-\ not\\:\\ 0\\.00400915153162966\ \(0\)\
\-\ a\\:\\ 0\\.0038629850826487136\ \(0\)\
\-\ pain\\:\\ 0\\.0033883382062686192\ \(0\)\
\-\ right\\:\\ 0\\.0029273756789299243\ \(0\)\
\-\ patient\\:\\ 0\\.0027811426328454157\ \(0\)\
\-\ of\\:\\ 0\\.002647813654499737\ \(0\)\
\-\ \\.\\:\\ 0\\.002420422915728155\ \(0\)\
\-\ for\\:\\ 0\\.0023672342488399844\ \(0\)\
\-\ and\\:\\ 0\\.0023377792952236163\ \(0\)\
\-\ with\\:\\ 0\\.0022793021316212287\ \(0\)\
